Helixgate

Helixgate

Uncategorized

This week in Drug Discovery (6 – 10 April) 

Published

on

News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW. 

This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration. 

The top stories: 

 

Research uncovers previously unknown recessive condition 


Researchers have discovered how genetic mutations can cause neuro-developmental disorders, including a previously unknown recessive condition.  

Read more… 

Trial to test CAR T-cell therapies as childhood cancer cures  


A first-of-its-kind trial has launched to explore whether personalised CAR T-cell immunotherapy could treat childhood cancers. 

Read more… 

 

FDA approves Lilly’s GLP-1 pill for weight loss 


The US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.   

Read more… 

 

 

AC Immune and Lilly reach agreement on drug collaboration  


Biopharmaceutical company AC Immune has reached an amended agreement with Eli Lilly for the development of an Alzheimer’s treatment. 

Read more… 

 

 

Alzheon doses first patient with novel Alzheimer’s drug  


The first patient has been dosed in Alzheon’s Phase I trial of its Alzheimer’s drug.  

Read more… 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The post This week in Drug Discovery (6 – 10 April)  appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Amgen shores up Tavneos’ FDA defense with Duke data analysis

Amgen shores up Tavneos’ FDA defense with Duke data analysis

Published

on

After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval.​ ​Read More

Continue Reading

Uncategorized

Chile offers new data on food warning label efficacy

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.

Read the rest…

Read More

Continue Reading

Uncategorized

Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win

Published

on

The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.

Continue Reading
Advertisement

Trending